P roton pump inhibitors (PPIs) are often prescribed together with antiplatelet therapy to prevent gastrointestinal complications, such as ulceration and bleeding. Clopidogrel, a potent antiplatelet used in the treatment of patients with coronary artery disease, 1 is a prodrug that requires metabolic transformation in the liver by cytochrome P-450 isoenzyme (CYP2C19) to acquire its antiaggregation properties. PPIs are also metabolized by CYP enzymes, leading to a potential competitive inhibition of CYP2C19 and reduced activation of clopidogrel when used together.
Data Extraction and Quality Assessment
Two investigators independently reviewed titles, abstracts, and fulltext articles for eligibility. We included original studies that were comparative assessments of strategies for treating patients with UA/ NSTEMI with an indication for DAPT and who were discharged on PPIs. For this analysis, we excluded studies if (1) the population was composed entirely of STEMI or stable angina patients, (2) all patients included in the study received PPIs, (3) the outcomes of interest were not reported, or (4) the studies were nonclinical (eg, editorial, letter to the editor, and case series).
One investigator abstracted data on general study characteristics, study population, eligibility criteria, treatment strategy, clinical outcomes, and safety using standardized forms. A second investigator over-read the abstraction to check for accuracy and completeness. We used predefined criteria 12 to assess study quality using the summary ratings of good (low risk of bias), fair (moderate risk), or poor (high risk). To assess study applicability, we evaluated the study eligibility criteria, study population demographics, clinical relevance, and timing of the outcome measures.
Data Synthesis and Analysis
We synthesized the primary literature by continuous data (eg, age and event rates) and categorical data (eg, race/ethnicity). Feasibility of completing a quantitative synthesis (meta-analysis) was based on the volume of relevant literature, conceptual homogeneity of the studies, and completeness of the reporting of results. We considered metaanalysis for comparisons where ≥3 separate studies reported data for the same outcome at a similar time of follow-up. Meta-analyses were based on the nature of the outcome variable, but random-effects models were used for all outcomes to accommodate the heterogeneity of the studies. Dichotomous outcome measures comparing 2 treatments were combined using hazard ratios (HRs) and a random-effects model using Comprehensive Meta-Analysis version 2 software (Biostat; Englewood, NJ).
Some studies reported only standard-adjusted results, others only propensity-adjusted results, and some reported both. For each outcome evaluated, we first performed a meta-analysis comparing the 2 types of estimates and looked for potential differences. As a second step, we did a meta-analysis using the propensity-adjusted HR (P) when it was available and the standard-adjusted HR (A) when the propensity-adjusted ratio was not available. We tested for statistical heterogeneity between studies (Q and I 2 statistics) while recognizing that the power to detect such heterogeneity may be limited. Potential heterogeneity between studies was determined by evaluating the range of confidence intervals (CIs) of the random-effects summary statistics.
We assessed the strength of evidence using the 4 required domains: risk of bias, consistency, directness, and precision. 12 We graded the strength of evidence for each outcome; thus, a given study may be of different quality for 2 individual outcomes reported within that same study. The studies were evaluated for the presence of confounders that would diminish an observed effect, strength of association (magnitude of effect), and publication bias. These domains were considered qualitatively, and a summary rating of high, moderate, or low strength of evidence was assigned.
Results
Thirty-five studies (4 randomized controlled trials [RCTs] and 31 observational) assessed the effect of antiplatelet therapy coadministered with PPI compared with DAPT alone (ie, no PPI) in the postdischarge treatment of patients with UA/ NSTEMI (Appendix Table I in the Data Supplement). 5, 8, 9, Four studies, consisting of 3 RCTs 15,21,33 and 1 observational study 44 in 5183 patients with UA/NSTEMI, assessed the effect of omeprazole added to DAPT; and 1 RCT 28 compared esomeprazole with famotidine for the prevention of gastrointestinal bleeding. The other 30 studies, all observational, assessed the
WHAT IS KNOWN
• A significant decrease in the effect of clopidogrel on platelet aggregation when coadministered with proton pump inhibitor (PPI) omeprazole has been reported in several pharmacodynamic studies. The clinical effect of the pharmacodynamic interaction between PPIs and clopidogrel remains unclear because results from observational studies have been discordant. • The Food and Drug Administration and EMEA discourage the combination of clopidogrel and omeprazole
WHAT THE STUDY ADDS
• Using a systematic review approach, we evaluated the effectiveness and safety of PPIs when coadministered with clopidogrel in unstable angina/non-STsegment-elevation myocardial infarction population. • Omeprazole was the only PPI studied in randomized controlled trials. Results from randomized controlled trials did not show increased risk of ischemic events when omeprazole was coadministered with clopidogrel. • A systematic assessment of the data obtained from observation studies suggested increased risk of cardiovascular outcomes when PPIs (as a class) were coadministered with clopidogrel. However, questions remain on the causality of this association, and even models and propensity scores adopted in observational data may have not fully addressed biases in patients selection. Overall, the systematic review of available evidence suggests the need of future randomized studies combining the assessment of pharmacodynamic parameters and their association with clinical outcomes.
effect of PPIs as a class compared with no PPI in the setting of DAPT. The summary results and strength of evidence ratings are shown in the Table.
Effect on Composite Ischemic End Point at ≈1 Year
The RCT comparing omeprazole with famotidine 28 reported a nonsignificant difference in the rate of composite outcomes (cardiovascular mortality, nonfatal MI, or stroke) at 4 months between the 2 groups (4.3% versus 3.4%; P=0.7788). Another RCT 15 comparing omeprazole with placebo reported a nonsignificant difference in the rate of composite outcomes (cardiovascular mortality, nonfatal MI, stroke, or revascularization) at 6 months between the 2 arms (4.9% versus 5.7%; HR, 0.99; 95% CI, 0.68-1.44; P=0.96). Similarly, an observational study 44 comparing omeprazole versus no omeprazole reported a nonsignificant difference in the rate of composite outcomes (cardiovascular mortality or nonfatal MI) at 12 months between the 2 groups (10% versus 9.7%; unadjusted HR, 1.1; 95% CI, 0.6-1.8; P=0.89). Twenty observational studies reported the effect of any PPI on the composite end point of all-cause mortality, stroke, or MI at 6 to 18 months. 5, 8, 13, [17] [18] [19] [22] [23] [24] [25] 27, [30] [31] [32] 34, 35, 37, 39, 42, 43 Ten reported only standard-adjusted results, 3 only propensity-adjusted results, and 7 reported both. The overall estimate for the standard-adjusted HRs was 1.40, whereas the overall estimate for the propensity-adjusted HRs was 1.34. (χ 2 =0.111 for 1 degree of freedom; P=0.739). Figure 2A shows the propensity-adjusted HR (P) when it was available and the standard-adjusted HR (A) when the propensity-adjusted HR was not available. The random-effects combined estimate was 1.35 (95% CI, 1.18-1.54; P<0.001; low-strength evidence).
Effect on Composite End Point of All-Cause Mortality or Nonfatal MI at ≈1 Year
Three observational studies with 60 389 patients reported the effect of any PPI on all-cause mortality or MI at 6 to 18 months. 13, 23, 31 One reported only standard-adjusted results, and 2 reported both standard and propensity-adjusted results. The overall estimate for the standard-adjusted HRs was 1.23, the estimate for the propensity-adjusted HRs was 1.31 (χ 2 =0.265 for 1 degree of freedom; P=0.607). Figure 2B shows that the random-effects combined estimate was 1.27 (95% CI, 1.12-1.43; P<0.001; moderate-strength evidence).
Effect on All-Cause Mortality at ≈1 Year
Three studies of omeprazole (2 RCTs and 1 observational) reported all-cause or cardiovascular mortality within at 6 to 18 months. One RCT 21 comparing omeprazole with placebo in 237 patients with acute MI reported a significant difference in all-cause mortality at 14 days favoring omeprazole (3.5% versus 10.6%; P=0.035). One RCT 15 comparing omeprazole with placebo in a mixed population of 3873 acute coronary syndrome and percutaneous coronary intervention (PCI patients) reported a nonsignificant difference in all-cause mortality at 6 months between omeprazole and placebo (4% versus 5%). Similarly, an observational study 44 comparing omeprazole versus no omeprazole in a mixed population of 558 stable angina and patients with acute coronary syndrome reported a nonsignificant difference in cardiovascular mortality at 1 year between omeprazole and placebo (3.5% versus 3.2%; unadjusted HR, 1.10; 95% CI, 0.44-2.84; P=0.84).
Of the 17 observational studies that reported the effect of any PPI on all-cause mortality at 6 to 18 mon ths, 5 reported both. The overall estimates for the standard-adjusted HRs and propensity-adjusted HRs were 1.18 and 1.44, respectively (χ 2 =1.271 for 1 degree of freedom; P=0.258). Figure 2C shows that the random-effects combined estimate was 1.17 (95% CI, 0.92-1.48; P=0.20; moderate-strength evidence).
Effect on Nonfatal MI at ≈1 Year
Two studies (1 RCT and 1 observational) of omeprazole reported nonfatal MI within the first year. The RCT 15 found a nonsignificant reduction of nonfatal MI at 6 months (1.2% versus 1.5%; HR, 0.92; 95% CI, 0.44-1.90; P=0.81) with omeprazole. Similarly, the observational study 44 found no effect of omeprazole versus no omeprazole on nonfatal MI (6.5% versus 6.5%; HR, 1.0; 95% CI, 0.5-1.9). Ten observational studies reported the effect of any PPI use on nonfatal MI at 6 to 18 months. 5 reported only standard-adjusted results, 3 both standard and propensity-adjusted-results, and 1 reported only propensity-adjusted results. The overall estimate for the standardadjusted and propensity-adjusted HRs was 1.35 and 1.33, respectively (χ 2 =0.005 for 1 degree of freedom; P=0.941). Figure 2D shows that the random-effects combined estimate was 1.33 (95% CI, 1.15-1.55; P<0.001; low-strength evidence).
Effect on Stroke at 30 Days and at ≈1 Year
Nonsignificant differences were found in the rate of both transient ischemic attacks at 30 days (2.3% versus 1.0%) 33 and stroke events at 6 months (stroke 0.2% versus 0.3%) 15 between patients treated with omeprazole compared with those receiving placebo. Five observational studies reported the effect of any PPI on stroke at 6 to 18 months. 17, 18, 27, 32, 42 Four reported only standard-adjusted results, and one reported both standard and propensity-adjusted results. Figure 2E shows that the random-effects combined estimate was 1.49 (95% CI, 1.20-1.84; P<0.001; low-strength evidence).
Effect on Revascularization at ≈1 Year
One RCT 15 found a similar rate of revascularization at 6 months among patients discharged on omeprazole compared with those discharged without (4.0% versus 4.6%). One observational study 31 similarly found no difference in the risk of revascularization at 6 months among 22 326 patients with UA/ NSTEMI treated at discharge with PPI compared with those not treated with PPI (adjusted HR, 0.97; 95% CI, 0.79-1.21; low-strength evidence). One observational study 44 found a similar rate of revascularization at 1 year for 588 patients with UA/NSTEMI discharged on omeprazole compared with those discharged without omeprazole (9.4% versus 8.9%).
A random-effects meta-analysis of 4 observational studies of any PPI, 8, 13, 27, 30 including 52 576 patients with UA/ NSTEMI assessing revascularization at 1 year reported standard-adjusted results, and 1 study additionally reported propensity-adjusted results. 13 Figure 2F shows that the random-effects combined estimate was 1.48 (95% CI, 1.21-1.82; low-strength evidence). There was evidence of heterogeneity that seemed to be because of the Banerjee study. 13 As a sensitivity analysis, we performed a meta-analysis where we used only the adjusted HR from the Banerjee study. The randomeffects combined estimate was 1.438 (95% CI, 1.215-1.703; Q=13.347 for 3 degrees of freedom; P=0.004; I 2 =77.523), indicating evidence of heterogeneity that was because of the Ortolani study estimate. 30
Effect on Stent Thrombosis at ≈1 Year
Two studies (1 RCT and 1 observational) of omeprazole reported stent thrombosis (definite, possible, and probable) within 1 year. In the RCT, 15 2 cases of definite or probable stent thrombosis occurred at 6 months in the placebo group, and no cases occurred in the omeprazole group. A nonsignificant difference in stent thrombosis was found among patients discharged on omeprazole compared with those discharged without (8.8% versus 5.8%; HR, 1.1; 95% CI, 0.7-1.8) at 1 year in the observational study. 44 Six observational studies reported the effect of any PPI use on stent thrombosis at 6 to 18 months. 5, 23, 25, 34, 35, 39 Four reported only standard-adjusted results, and 2 only propensity-adjusted results. The overall estimate for the standard-adjusted and for propensity-adjusted HRs was 1.35 and 1.33, respectively (χ 2 =0.005 for 1 degree of freedom; P=0.941). 15, 21, 28, 33 Figure 2G shows that the random-effects combined estimate was 1.34 (95% CI, 1.17-1.55; P<0.001; low-strength evidence).
Effect on Gastrointestinal Bleeding
Four RCTs of omeprazole reported gastrointestinal bleeding. 15, 21, 28, 33 Three found that the use of omeprazole significantly reduced the rates of upper gastrointestinal bleeding at 14 days and at 4 and 6 months.
Four observational studies of any PPIs reported on gastrointestinal bleeding. 14, 19, 29, 32 One 14 found no difference in the rate of in-hospital gastrointestinal bleeding between patients discharged with and without PPI (0.7% versus 0.6%; P=0.88). Another 29 found a significant increase in the rate of in-hospital gastrointestinal bleeding among patients not receiving PPI compared with those treated with PPI (4.8% versus 0.6%; P=0.001). The 2 studies reporting gastrointestinal events at longer follow-up found dissimilar results. One 19 found no differences in gastrointestinal bleeding at 18 months between patients with UA/NSTEMI treated with or without PPI (3.5% versus 3.8%; HR, 0.39; 95% CI, 0.04-3.26; P=0.38). The other 32 found a significant reduction in gastrointestinal bleeding at 1 year among patients treated with PPI compared with those not treated with PPI (HR, 0.50; 95% CI, 0.39-0.65).
Given the differences in the duration of follow-up both in the RCTs and observational studies, a meta-analysis was not performed; however, there is moderate-strength evidence that favors use of PPIs for reducing gastrointestinal bleeding.
Discussion
Using a systematic review approach, we found that among patients with UA/NSTEMI with an indication for DAPT, the concomitant administration of PPIs (as a class) was associated with worse clinical outcomes in observational studies; however, 4 RCTs of omeprazole versus placebo report no difference in ischemic outcomes despite reducing upper gastrointestinal bleeding with omeprazole administration.
Several studies assessing platelet aggregation inhibition have shown how PPIs may significantly reduce the antiplatelet effect of clopidogrel when the 2 drugs are coadministered. [2] [3] [4] [5] This effect is attributed to an important pharmacokinetic interaction between the 2 drugs, where clopidogrel needs metabolic transformation to its active form by CYP2C19 enzyme, and PPIs inhibit this enzyme to different extents.
The findings from pharmacodynamic studies have not fully translated into a difference in clinical outcomes because multiple studies exploring the effect of concomitant use of PPIs and clopidogrel on major cardiovascular outcomes have found contrasting results. 8, 9, 45, 46 In our analysis of the use of PPIs with DAPT, we identified 35 studies, of which only 4 were RCTs. All RCTs investigating the effect of omeprazole compared with placebo or esomeprazole compared with famotidine (1 study) on cardiovascular outcomes showed no difference in ischemic events. The use of omeprazole did result in a significant reduction in gastrointestinal bleeding; however, given the differences in the timing of follow-up (from 14 days to 6 months), a meta-analysis was not considered applicable. Although a net clinical benefit analysis was not performed, these data suggest that omeprazole and clopidogrel can be safely coadministered. These findings all based on RCTs call into question the Food and Drug Administration warning against the concomitant use of clopidogrel plus omeprazole.
Data obtained from the remaining 30 studies (all observational) comparing PPI medication (as a class) with no PPI medication suggest that event rates are higher in patients who receive any type of PPI medication for the composite outcome (all-cause mortality or nonfatal MI) at 1 year, and nonfatal MI, all-cause mortality, and revascularization after 1 year. The potential for selection bias in observational trials is not negligible. Sicker patients, with more comorbidities and at higher baseline risk for adverse outcomes, are preferentially treated with PPI therapy, and as a result this cohort seems to have more adverse clinical outcomes. 8, 17 In an attempt to account for some of these baseline differences between patients who received PPI and those who did not, we used the results for standard and propensity score-matched HRs for each study. Also, when possible, we ran separate meta-analyses to assess the effect of adjustment on the clinical outcomes. For a majority of analyses, there was no statistically significant difference in the summary estimate for the standard-adjustment compared with the propensityadjusted HRs. Many of the meta-analyses showed evidence of heterogeneity that is likely because of the variation in the clinical factors used to calculate the standard and propensity-adjusted HRs. The summary estimates for the standard/ propensity-adjusted results showed HRs that were closer to 1, but for many outcomes the summary estimate still favored the no PPI group.
Aside from the underlying differences in patients' baseline characteristics and comorbidities that were observed in the analysis population of the observational studies, there are other important factors to consider when comparing results from RCTs and observational studies. Among them, we found that observational studies lacked information on the PPI regimen, such as the dose and frequency of administration, the duration of treatment, concomitant medications, new prescription versus chronic therapy, and patients' medication adherence.
Although we attempted to control for some of these confounding factors inherent to patient and clinical characteristics, it is highly probable that unmeasurable confounding still remains, and the effect of PPIs analyzed as a class in this analysis is not based on strong evidence. 47 It is also unclear whether genetic resistance to clopidogrel is a causal factor, or whether the negative interaction may be drug specific or class specific. Those variables were not included in the studies we reviewed. The overall strength of evidence rating was downgraded because the findings from observational studies on PPI as a class conflicted with the few RCTs of omeprazole.
Study type and method of analysis can explain some variation in the relative hazard associated with the coadministration of PPI with clopidogrel; the risk of error is mitigated as the methodological rigor increases. 42, 47, 48 A recent update of the American Heart Association/ American College of Cardiology guidelines has removed the recommendation to administer PPI to patients with a history of gastrointestinal bleeding, and in its place suggests that healthcare providers evaluate the need for starting or continuing PPI treatment in patients taking clopidogrel. Their statement does not prohibit the use of PPIs in appropriate clinical settings; however, they describe the potential risks and benefits from PPIs in combination with clopidogrel. 1 Our findings also support a cautious approach to PPI use with DAPT therapy in patients with UA/NSTEMI. Further research-preferably additional RCTs of specific PPI agents or prospective propensity score-matched cohort studies-is warranted on whether the detrimental effect of PPIs is because of comorbid conditions of the patient population, to the specific PPI agent used, or to genetic predisposition for reduced clopidogrel responsiveness.
Strengths and Limitations
Some considerations should be taken into account while interpreting these data. The strength of this review is its focus on comparative studies of antiplatelet and anticoagulant treatments; any studies that reported noncomparative findings were excluded. To review adequate numbers of studies to address the safety and effectiveness of PPIs when coadministered with DAPT in patients with UA/NSTEMI, we had to broaden our eligible patient population to include studies of either UA/ NSTEMI or acute coronary syndrome (STEMI, NSTEMI, and unstable angina). Also, some PPI studies included patients with acute coronary syndrome or stable angina. To improve the applicability of our findings to the UA/NSTEMI population, we did exclude studies that focused exclusively on the STEMI or stable angina population.
In addition, different composite end point definitions made quantitative analysis less feasible. Information on adherence to clopidogrel or PPI treatment, dose of PPI, or switching between one PPI and another was not available. Finally, an analysis of the net benefit was not conducted (ie, assessing the effectiveness while accounting for the risk of these therapies).
Conclusions
Although the use of PPIs as a class was associated with worse clinical outcomes in observational studies of patients with UA/NSTEMI receiving DAPT, the results from a small number of RCTs of omeprazole showed no significant difference in clinical events. Prospective trials directly comparing pharmacodynamic parameters and clinical events of different PPIs in patients with UA/NSTEMI treated with DAPT are warranted.
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